Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.
CRCI
Cancer
Cancer-related cognitive impairment
Chemotherapy-related cognitive impairment
Cognition
Cognitive functioning
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
07
08
2020
accepted:
26
10
2020
pubmed:
25
11
2020
medline:
18
5
2021
entrez:
24
11
2020
Statut:
ppublish
Résumé
Cancer-related cognitive impairment (CRCI) is commonly experienced by individuals with non-central nervous system cancers throughout the disease and treatment trajectory. CRCI can have a substantial impact on the functional ability and quality of life of patients and their families. To mitigate the impact, oncology providers must know how to identify, assess, and educate patients and caregivers. The objective of this review is to provide oncology clinicians with an overview of CRCI in the context of adults with non-central nervous system cancers, with a particular focus on current approaches in its identification, assessment, and management.
Identifiants
pubmed: 33231809
doi: 10.1007/s00520-020-05860-9
pii: 10.1007/s00520-020-05860-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2821-2840Références
Wefel JS, Kesler SR, Noll KR, Schagen SB (2015) Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 65(2):123–138. https://doi.org/10.3322/caac.21258
doi: 10.3322/caac.21258
pubmed: 25483452
Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, Joly F (2019) Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey. Cancer Med 8(5):2654–2663. https://doi.org/10.1002/cam4.2069
doi: 10.1002/cam4.2069
pubmed: 30884207
pmcid: 6536919
Von Ah D, Storey S, Tallman E, Nielsen A, Johns SA, Pressler S (2016) Cancer, cognitive impairment, and work-related outcomes: an integrative review. Oncol Nurs Forum 43(5):602–616. https://doi.org/10.1188/16.onf.602-616
doi: 10.1188/16.onf.602-616
Potrata B, Cavet J, Blair S, Howe T, Molassiotis A (2010) 'Like a sieve': an exploratory study on cognitive impairments in patients with multiple myeloma. Eur J Cancer Care 19(6):721–728. https://doi.org/10.1111/j.1365-2354.2009.01145.x
doi: 10.1111/j.1365-2354.2009.01145.x
Shilling V, Jenkins V (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11(1):6–15. https://doi.org/10.1016/j.ejon.2006.02.005
doi: 10.1016/j.ejon.2006.02.005
pubmed: 16844416
Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232. https://doi.org/10.1007/s11764-009-0098-x
doi: 10.1007/s11764-009-0098-x
pubmed: 19760150
pmcid: 2775113
Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, Kim DD, Piescic C, Breen D, Lambie A, Loach D, Michelis FV, Alam N, Uhm J, McGillis L, Metcalfe K (2016) Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. Bone Marrow Transplant 51(6):841–847. https://doi.org/10.1038/bmt.2016.2
doi: 10.1038/bmt.2016.2
pubmed: 26926230
Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9(7):967–982. https://doi.org/10.1017/S1355617703970019
doi: 10.1017/S1355617703970019
pubmed: 14738279
Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE (2018) Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and quality of life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 24(2):228–241. https://doi.org/10.1016/j.bbmt.2017.09.004
doi: 10.1016/j.bbmt.2017.09.004
pubmed: 28939455
Phillips KM, McGinty HL, Cessna J, Asvat Y, Gonzalez B, Cases MG, Small BJ, Jacobsen PB, Pidala J, Jim HS (2013) A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation. Bone Marrow Transplant 48(10):1350–1357. https://doi.org/10.1038/bmt.2013.61
doi: 10.1038/bmt.2013.61
pubmed: 23645166
pmcid: 3770806
Williams AM, Zent CS, Janelsins MC (2016) What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol 174(6):835–846. https://doi.org/10.1111/bjh.14211
doi: 10.1111/bjh.14211
pubmed: 27391367
pmcid: 5626568
Treanor CJ, Li J, Donnelly M (2017) Cognitive impairment among prostate cancer patients: an overview of reviews. Eur J Cancer Care 26(6). https://doi.org/10.1111/ecc.12642
Janelsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry (Abingdon, England) 26(1):102–113. https://doi.org/10.3109/09540261.2013.864260
doi: 10.3109/09540261.2013.864260
pmcid: 4084673
Schmidt J, Beckjord E, Bovbjerg D, Low C, Posluszny D, Lowery A, Dew M, Nutt S, Arvey S, Rechis R (2015) Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey. J Cancer Surviv:1–10. https://doi.org/10.1007/s11764-015-0476-5
Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19(4):623–629. https://doi.org/10.1093/annonc/mdm500
doi: 10.1093/annonc/mdm500
pubmed: 17974553
Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U (2007) The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66(1):108–118. https://doi.org/10.1016/j.pec.2006.11.005
doi: 10.1016/j.pec.2006.11.005
pubmed: 17320337
Santos JC, Pyter LM (2018) Neuroimmunology of behavioral comorbidities associated with cancer and cancer treatments. Front Immunol 9:1195. https://doi.org/10.3389/fimmu.2018.01195
doi: 10.3389/fimmu.2018.01195
pubmed: 29930550
pmcid: 6001368
Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA (2011) A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19(10):1647–1656. https://doi.org/10.1007/s00520-010-0997-4
doi: 10.1007/s00520-010-0997-4
pubmed: 20820813
Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092. https://doi.org/10.1200/jco.2015.63.0905
doi: 10.1200/jco.2015.63.0905
pubmed: 26527785
pmcid: 5683012
Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L, Gritz ER (2011) Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 117(1):190–196. https://doi.org/10.1002/cncr.25298
doi: 10.1002/cncr.25298
pubmed: 20737560
Piai V, Prins JB, Verdonck-de Leeuw IM, Leemans CR, Terhaard CHJ, Langendijk JA, Baatenburg de Jong RJ, Smit JH, Takes RP, Kessels RPC (2019) Assessment of neurocognitive impairment and speech functioning before head and neck cancer treatment. JAMA Otolaryngol Head Neck Surg. https://doi.org/10.1001/jamaoto.2018.3981
Hshieh TT, Jung WF, Grande LJ, Chen J, Stone RM, Soiffer RJ, Driver JA, Abel GA (2018) Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers. JAMA Oncol 4(5):686–693. https://doi.org/10.1001/jamaoncol.2017.5674
doi: 10.1001/jamaoncol.2017.5674
pubmed: 29494732
pmcid: 5885202
Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J (2013) Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev 37(8):1311–1321. https://doi.org/10.1016/j.neubiorev.2013.04.015
doi: 10.1016/j.neubiorev.2013.04.015
pubmed: 23660455
Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30(29):3578–3587. https://doi.org/10.1200/jco.2011.39.5640
doi: 10.1200/jco.2011.39.5640
pubmed: 22927526
pmcid: 3462044
Ono M, Ogilvie JM, Wilson JS, Green HJ, Chambers SK, Ownsworth T, Shum DH (2015) A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol 5:59. https://doi.org/10.3389/fonc.2015.00059
doi: 10.3389/fonc.2015.00059
pubmed: 25806355
pmcid: 4354286
Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39(3):297–304. https://doi.org/10.1016/j.ctrv.2012.11.001
doi: 10.1016/j.ctrv.2012.11.001
pubmed: 23219452
Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 35(5):506–514. https://doi.org/10.1200/jco.2016.68.5826
doi: 10.1200/jco.2016.68.5826
pubmed: 28029304
Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, Palesh O, O'Mara AM, Minasian LM, Williams AM, Magnuson A, Geer J, Dakhil SR, Hopkins JO, Morrow GR (2018) Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. J Clin Oncol:Jco2018786624. https://doi.org/10.1200/jco.2018.78.6624
Hosseini SM, Koovakkattu D, Kesler SR (2012) Altered small-world properties of gray matter networks in breast cancer. BMC Neurol 12:28. https://doi.org/10.1186/1471-2377-12-28
doi: 10.1186/1471-2377-12-28
pubmed: 22632066
pmcid: 3404945
Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10(1):33–41. https://doi.org/10.1046/j.1525-1438.2000.00003.x
doi: 10.1046/j.1525-1438.2000.00003.x
pubmed: 11240649
Pendergrass JC, Targum SD, Harrison JE (2018) Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci 15(1-2):36–44
pubmed: 29497579
pmcid: 5819720
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123(3):819–828. https://doi.org/10.1007/s10549-010-1088-4
doi: 10.1007/s10549-010-1088-4
pubmed: 20690040
pmcid: 3661415
Geraghty AC, Gibson EM, Ghanem RA, Greene JJ, Ocampo A, Goldstein AK, Ni L, Yang T, Marton RM, Pasca SP, Greenberg ME, Longo FM, Monje M (2019) Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment. Neuron 103(2):250–265.e258. https://doi.org/10.1016/j.neuron.2019.04.032
doi: 10.1016/j.neuron.2019.04.032
pubmed: 31122677
pmcid: 6697075
Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN, Greene JJ, Geraghty AC, Goldstein AK, Ni L, Woo PJ, Barres BA, Liddelow S, Vogel H, Monje M (2019) Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell 176(1-2):43–55.e13. https://doi.org/10.1016/j.cell.2018.10.049
doi: 10.1016/j.cell.2018.10.049
pubmed: 30528430
Rogers LR (2012) Neurologic complications of radiation. Continuum (Minneap Minn) 18(2):343–54. https://doi.org/10.1212/01.CON.0000413662.35174
doi: 10.1212/01.CON.0000413662.35174
pubmed: 22810131
Wilke C, Grosshans D, Duman J, Brown P, Li J (2018) Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults. Neuro-Oncology 20(5):597–607. https://doi.org/10.1093/neuonc/nox195
doi: 10.1093/neuonc/nox195
pubmed: 29045710
Dong X, Luo M, Huang G, Zhang J, Tong F, Cheng Y, Cai Q, Dong J, Wu G, Cheng J (2015) Relationship between irradiation-induced neuro-inflammatory environments and impaired cognitive function in the developing brain of mice. Int J Radiat Biol 91(3):224–239. https://doi.org/10.3109/09553002.2014.988895
doi: 10.3109/09553002.2014.988895
pubmed: 25426696
Carvalho HA, Villar RC (2018) Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo, Brazil) 73(suppl 1):e557s–e557s. https://doi.org/10.6061/clinics/2018/e557s
doi: 10.6061/clinics/2018/e557s
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690
doi: 10.1056/NEJMoa1200690
pubmed: 22658127
pmcid: 22658127
McGinnis GJ, Raber J (2017) CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy 9(11):929–941. https://doi.org/10.2217/imt-2017-0056
doi: 10.2217/imt-2017-0056
pubmed: 29338610
pmcid: 6161123
McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR Jr, Gough MJ, Raber J (2017) Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget 8(6):9155–9173. https://doi.org/10.18632/oncotarget.13551
doi: 10.18632/oncotarget.13551
pubmed: 27893434
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983. https://doi.org/10.1016/s1470-2045(16)30053-5
doi: 10.1016/s1470-2045(16)30053-5
pubmed: 27267608
pmcid: 5526047
Joly F, Castel H, Tron L, Lange M, Vardy J (2020) Potential effect of immunotherapy agents on cognitive function in cancer patients. J Natl Cancer Inst 112(2):123–127. https://doi.org/10.1093/jnci/djz168
doi: 10.1093/jnci/djz168
pubmed: 31504664
Fathpour P, Obad N, Espedal H, Stieber D, Keunen O, Sakariassen PO, Niclou SP, Bjerkvig R (2014) Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment? Neuro-Oncol 16(5):754–756. https://doi.org/10.1093/neuonc/nou013
doi: 10.1093/neuonc/nou013
pubmed: 24733853
pmcid: 3984560
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573
doi: 10.1056/NEJMoa1308573
pubmed: 24552317
pmcid: 4201043
Ng T, Phey XY, Yeo HL, Shwe M, Gan YX, Ng R, Ho HK, Chan A (2018) Impact of adjuvant anthracycline-based and taxane-based chemotherapy on plasma VEGF levels and cognitive function in breast cancer patients: a longitudinal study. Clin Breast Cancer 18(5):e927–e937. https://doi.org/10.1016/j.clbc.2018.03.016
doi: 10.1016/j.clbc.2018.03.016
pubmed: 29705024
Mulder SF, Bertens D, Desar IM, Vissers KC, Mulders PF, Punt CJ, van Spronsen DJ, Langenhuijsen JF, Kessels RP, van Herpen CM (2014) Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. BMC Cancer 14:219. https://doi.org/10.1186/1471-2407-14-219
doi: 10.1186/1471-2407-14-219
pubmed: 24661373
pmcid: 3987809
Wick W, Hertenstein A, Platten M (2016) Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 17(12):e529–e541. https://doi.org/10.1016/S1470-2045(16)30571-X
doi: 10.1016/S1470-2045(16)30571-X
pubmed: 27924751
Ulm M, Ramesh AV, McNamara KM, Ponnusamy S, Sasano H, Narayanan R (2019) Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocr Connect 8(2):R10–r26. https://doi.org/10.1530/ec-18-0425
doi: 10.1530/ec-18-0425
pubmed: 30640710
pmcid: 6365668
Luine VN (2014) Estradiol and cognitive function: past, present and future. Horm Behav 66(4):602–618. https://doi.org/10.1016/j.yhbeh.2014.08.011
doi: 10.1016/j.yhbeh.2014.08.011
pubmed: 25205317
pmcid: 4318702
Bean LA, Ianov L, Foster TC (2014) Estrogen receptors, the hippocampus, and memory. Neuroscientist 20(5):534–545. https://doi.org/10.1177/1073858413519865
doi: 10.1177/1073858413519865
pubmed: 24510074
pmcid: 4317255
Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, Casillo FE, Dailey MM, Erickson KI, Kratofil FM, McAuliffe PF, Rosenzweig MQ, Ryan CM, Sereika SM (2015) Patterns of change in cognitive function with anastrozole therapy. Cancer 121(15):2627–2636. https://doi.org/10.1002/cncr.29393
doi: 10.1002/cncr.29393
pubmed: 25906766
Ganz PA, Petersen L, Bower JE, Crespi CM (2016) Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the mind-body study. J Clin Oncol 34(8):816–824. https://doi.org/10.1200/JCO.2015.64.3866
doi: 10.1200/JCO.2015.64.3866
pubmed: 26786934
pmcid: 4872009
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294–1300. https://doi.org/10.1200/JCO.2008.21.3553
doi: 10.1200/JCO.2008.21.3553
pubmed: 20142601
Underwood EA, Jerzak KJ, Lebovic G, Rochon PA, Elser C, Pritchard KI, Tierney MC (2019) Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study. Support Care Cancer. https://doi.org/10.1007/s00520-018-4603-5
Van Dyk K, Crespi CM, Bower JE, Castellon SA, Petersen L, Ganz PA (2019) The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment. Cancer 125(5):681–689. https://doi.org/10.1002/cncr.31858
doi: 10.1002/cncr.31858
pubmed: 30485399
Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ (2005) Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103(7):1381–1387. https://doi.org/10.1002/cncr.20962
doi: 10.1002/cncr.20962
pubmed: 15717315
Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, Sun C, Francisco L, Forman SJ, Wong FL, Bhatia S (2018) Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: results from a prospective longitudinal study. J Clin Oncol 36(5):463–475. https://doi.org/10.1200/jco.2017.74.2270
doi: 10.1200/jco.2017.74.2270
pubmed: 29252122
Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB, Dikmen S (2011) Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. https://doi.org/10.1200/jco.2010.33.9119
Reid-Arndt SA, Cox CR (2012) Stress, coping and cognitive deficits in women after surgery for breast cancer. J Clin Psychol Med Settings 19(2):127–137. https://doi.org/10.1007/s10880-011-9274-z
doi: 10.1007/s10880-011-9274-z
pubmed: 22231422
Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S, Welsh RC (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32(3):324–331. https://doi.org/10.1080/13803390903032537
doi: 10.1080/13803390903032537
pubmed: 19642048
Su Y, Pu Y, Zhao Z, Yang X (2020) Influence of combined epidural anesthesia on cognitive function, inflammation and stress response in elderly liver cancer patients undergoing surgery. Oncol Lett 19(4):2733–2738. https://doi.org/10.3892/ol.2020.11395
doi: 10.3892/ol.2020.11395
pubmed: 32218825
pmcid: 7068239
Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A, Jacobsen PB, Faul LA, Isaacs C, Denduluri N, Gavett B, Traina TA, Johnson P, Silliman RA, Turner RS, Howard D, Van Meter JW, Saykin A, Ahles T (2014) Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol 32(18):1909–1918. https://doi.org/10.1200/jco.2013.54.2050
doi: 10.1200/jco.2013.54.2050
pubmed: 24841981
pmcid: 4050204
Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, Kim DDH, McGillis L, Uhm J, Michelis FV, Alam N, Lambie A, Breen D, Loach D, Piescic C, Metcalfe K (2015) Predictors of the trajectory of neurocognitive functioning in the first six months after allogeneic hematopoietic stem cell transplantation. Blood 126(23):3289
doi: 10.1182/blood.V126.23.3289.3289
Jim HSL, Small B, Hartman S, Franzen J, Millay S, Phillips K, Jacobsen PB, Booth-Jones M, Pidala J (2012) Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation. Cancer 118(13):3407–3416
doi: 10.1002/cncr.26645
McQuillan R, Jassal SV (2010) Neuropsychiatric complications of chronic kidney disease. Nat Rev Nephrol 6(8):471–479. https://doi.org/10.1038/nrneph.2010.83
doi: 10.1038/nrneph.2010.83
pubmed: 20567247
Watanabe K, Watanabe T, Nakayama M (2014) Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neurotoxicology 44:184–193. https://doi.org/10.1016/j.neuro.2014.06.014
doi: 10.1016/j.neuro.2014.06.014
pubmed: 25003961
Collie A (2005) Cognition in liver disease. Liver Int 25(1):1–8. https://doi.org/10.1111/j.1478-3231.2005.01012.x
doi: 10.1111/j.1478-3231.2005.01012.x
pubmed: 15698392
Huskisson E, Maggini S, Ruf M (2007) The influence of micronutrients on cognitive function and performance. J Int Med Res 35(1):1–19. https://doi.org/10.1177/147323000703500101
doi: 10.1177/147323000703500101
pubmed: 17408051
Miller JW, Harvey DJ, Beckett LA, Green R, Farias ST, Reed BR, Olichney JM, Mungas DM, DeCarli C (2015) Vitamin D status and rates of cognitive decline in a multiethnic cohort of older adults. JAMA Neurol 72(11):1295–1303. https://doi.org/10.1001/jamaneurol.2015.2115
doi: 10.1001/jamaneurol.2015.2115
pubmed: 26366714
pmcid: 5023277
Wittbrodt MT, Millard-Stafford M (2018) Dehydration impairs cognitive performance: a meta-analysis. Med Sci Sports Exerc 50(11):2360–2368. https://doi.org/10.1249/mss.0000000000001682
doi: 10.1249/mss.0000000000001682
pubmed: 29933347
Van Cutsem E, Arends J (2005) The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9(Suppl 2):S51–S63. https://doi.org/10.1016/j.ejon.2005.09.007
doi: 10.1016/j.ejon.2005.09.007
pubmed: 16437758
Rosner MH, Dalkin AC (2014) Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis 21(1):7–17. https://doi.org/10.1053/j.ackd.2013.05.005
doi: 10.1053/j.ackd.2013.05.005
pubmed: 24359982
Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17(1):146–150. https://doi.org/10.1093/annonc/mdj038
doi: 10.1093/annonc/mdj038
pubmed: 16251202
Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G (2006) Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 57(2):175–182. https://doi.org/10.1016/j.critrevonc.2005.06.001
doi: 10.1016/j.critrevonc.2005.06.001
pubmed: 16213740
Iconomou G, Koutras A, Karaivazoglou K, Kalliolias GD, Assimakopoulos K, Argyriou AA, Ifanti A, Kalofonos HP (2008) Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur J Cancer Care 17(6):535–541. https://doi.org/10.1111/j.1365-2354.2007.00857.x
doi: 10.1111/j.1365-2354.2007.00857.x
Fan HG, Park A, Xu W, Yi QL, Braganza S, Chang J, Couture F, Tannock IF (2009) The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2):156–161. https://doi.org/10.1002/pon.1372
doi: 10.1002/pon.1372
pubmed: 18561284
Von Ah D, Jansen CE, Allen DH (2014) Evidence-based interventions for cancer- and treatment-related cognitive impairment. Clin J Oncol Nurs 18(Suppl):17–25. https://doi.org/10.1188/14.cjon.s3.17-25
doi: 10.1188/14.cjon.s3.17-25
Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA (2003) The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-oncology 12(6):612–619. https://doi.org/10.1002/pon.742
doi: 10.1002/pon.742
pubmed: 12923801
Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, Graham D, Zhou X, Clapp J, Zhai W, Breen E, Carroll JE, Denduluri N, Dilawari A, Extermann M, Isaacs C, Jacobsen PB, Kobayashi LC, Holohan Nudelman K, Root J, Stern RA, Tometich D, Turner R, VanMeter JW, Saykin AJ, Ahles T (2018) Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J Clin Oncol:Jco1800140. https://doi.org/10.1200/jco.18.00140
Amidi A, Agerbaek M, Wu LM, Pedersen AD, Mehlsen M, Clausen CR, Demontis D, Borglum AD, Harboll A, Zachariae R (2017) Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav 11(3):769–783. https://doi.org/10.1007/s11682-016-9552-3
doi: 10.1007/s11682-016-9552-3
pubmed: 27240852
Cheng H, Li W, Gan C, Zhang B, Jia Q, Wang K (2016) The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res 8(11):5087–5097
pubmed: 27904710
pmcid: 5126352
Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, Andrykowski MA, Jacobsen PB (2011) Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 117(7):1369–1376. https://doi.org/10.1002/cncr.25685
doi: 10.1002/cncr.25685
pubmed: 21425136
Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WJ, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A (2016) Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol 18(2):244–251. https://doi.org/10.1093/neuonc/nov162
doi: 10.1093/neuonc/nov162
pubmed: 26289590
Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A (2018) Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. Mol Neurobiol. https://doi.org/10.1007/s12035-018-1410-4
Chan A, Yeo A, Shwe M, Tan CJ, Foo KM, Chu P, Khor CC, Ho HK (2019) An Evaluation of DNA Methyltransferase 1 (DNMT1) Single nucleotide polymorphisms and chemotherapy-associated cognitive impairment: a prospective, longitudinal study. Sci Rep 9(1):14570. https://doi.org/10.1038/s41598-019-51203-y
doi: 10.1038/s41598-019-51203-y
pubmed: 31601979
pmcid: 6787348
Ownby KK (2019) Use of the distress thermometer in clinical practice. J Adv Pract Oncol 10(2):175–179
pubmed: 31538028
pmcid: 6750919
Cormio C, Caporale F, Spatuzzi R, Lagattolla F, Lisi A, Graziano G (2019) Psychosocial distress in oncology: using the distress thermometer for assessing risk classes. Support Care Cancer 27(11):4115–4121. https://doi.org/10.1007/s00520-019-04694-4
doi: 10.1007/s00520-019-04694-4
pubmed: 30788626
National Comprehensive Cancer Network (2014) Survivorship, Version 2.2014. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network
Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, Group obotEQoL (2001) The EORTC QLQ-C30 Scoring Manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels
Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1–8. https://doi.org/10.1016/j.jclinepi.2019.10.003
doi: 10.1016/j.jclinepi.2019.10.003
pubmed: 31639445
Wagner L, Sweet J, Butt Z, Lai J, Cella D (2009) Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol 7:32–39
Bray VJ, Dhillon HM, Vardy JL (2018) Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv 12(4):537–559. https://doi.org/10.1007/s11764-018-0692-x
doi: 10.1007/s11764-018-0692-x
pubmed: 29728959
Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, Canin B, Cohen HJ, Holmes HM, Hopkins JO, Janelsins MC, Khorana AA, Klepin HD, Lichtman SM, Mustian KM, Tew WP, Hurria A (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol 36(22):2326–2347. https://doi.org/10.1200/jco.2018.78.8687
doi: 10.1200/jco.2018.78.8687
pubmed: 29782209
pmcid: 6063790
(1996) Mini-Mental State Examination (MMSE) and the Modified MMSE (3MS): a psychometric comparison and normative data, vol 8. American Psychological Association, US. https://doi.org/10.1037/1040-3590.8.1.48
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
doi: 10.1111/j.1532-5415.2005.53221.x
pubmed: 15817019
Isenberg-Grzeda E, Huband H, Lam H (2017) A review of cognitive screening tools in cancer. Curr Opin Support Palliat Care 11(1):24–31
doi: 10.1097/SPC.0000000000000257
Saria MG, Courchesne N, Evangelista L, Carter J, MacManus DA, Gorman MK, Nyamathi AM, Phillips LR, Piccioni D, Kesari S, Maliski S (2017) Cognitive dysfunction in patients with brain metastases: influences on caregiver resilience and coping. Support Care Cancer 25(4):1247–1256. https://doi.org/10.1007/s00520-016-3517-3
doi: 10.1007/s00520-016-3517-3
pubmed: 27921222
Kang JH, Shin SH, Bruera E (2013) Comprehensive approaches to managing delirium in patients with advanced cancer. Cancer Treat Rev 39(1):105–112. https://doi.org/10.1016/j.ctrv.2012.08.001
doi: 10.1016/j.ctrv.2012.08.001
pubmed: 22959227
Pereira J, Hanson J, Bruera E (1997) The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 79(4):835–842
doi: 10.1002/(SICI)1097-0142(19970215)79:4<835::AID-CNCR21>3.0.CO;2-#
Harada CN, Natelson Love MC, Triebel KL (2013) Normal cognitive aging. Clin Geriatr Med 29(4):737–752. https://doi.org/10.1016/j.cger.2013.07.002
doi: 10.1016/j.cger.2013.07.002
pubmed: 24094294
pmcid: 4015335
Ahles TA, Hurria A (2018) New Challenges in Psycho-Oncology Research IV: cognition and cancer: Conceptual and methodological issues and future directions. Psycho-oncology 27(1):3–9. https://doi.org/10.1002/pon.4564
doi: 10.1002/pon.4564
pubmed: 29044730
Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, Fuldner R, Ferrucci L, Gallicchio L, Gavrilov L, Gavrilova N, Green PA, Jhappan C, Kohanski R, Krull K, Mandelblatt J, Ness KK, O’Mara A, Price N, Schrack J, Studenski S, Theou O, Tracy RP, Hurria A (2019) Measuring aging and identifying aging phenotypes in cancer survivors. J Natl Cancer Inst 111(12):1245–1254. https://doi.org/10.1093/jnci/djz136
doi: 10.1093/jnci/djz136
pubmed: 31321426
pmcid: 7962788
Cheung YT, Tan EH-J, Chan A (2012) An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer 20(7):1361–1375. https://doi.org/10.1007/s00520-012-1445-4
doi: 10.1007/s00520-012-1445-4
pubmed: 22476439
Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934. https://doi.org/10.1016/j.ctrv.2012.05.002
doi: 10.1016/j.ctrv.2012.05.002
pubmed: 22658913
Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703–708. https://doi.org/10.1016/S1470-2045(10)70294-1
doi: 10.1016/S1470-2045(10)70294-1
pubmed: 21354373
Lange M, Joly F (2017) How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Practice 13(12):784–790. https://doi.org/10.1200/jop.2017.026286
doi: 10.1200/jop.2017.026286
Miller JB, Barr WB (2017) The technology crisis in neuropsychology. Arch Clin Neuropsychol 32(5):541–554. https://doi.org/10.1093/arclin/acx050
doi: 10.1093/arclin/acx050
pubmed: 28541383
Poppelreuter M, Weis J, Kulz AK, Tucha O, Lange KW, Bartsch HH (2004) Cognitive dysfunction and subjective complaints of cancer patients. a cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 40(1):43–49. https://doi.org/10.1016/j.ejca.2003.08.001
doi: 10.1016/j.ejca.2003.08.001
pubmed: 14687788
Srisurapanont M, Suttajit S, Eurviriyanukul K, Varnado P (2017) Discrepancy between objective and subjective cognition in adults with major depressive disorder. Sci Rep 7(1):3901. https://doi.org/10.1038/s41598-017-04353-w
doi: 10.1038/s41598-017-04353-w
pubmed: 28634383
pmcid: 5478612
Kim HJ, Barsevick AM, Fang CY, Miaskowski C (2012) Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. Cancer Nurs 35(6):E1–e20. https://doi.org/10.1097/NCC.0b013e318233a811
doi: 10.1097/NCC.0b013e318233a811
pubmed: 22228391
Von Ah D, Storey S, Jansen CE, Allen DH (2013) Coping strategies and interventions for cognitive changes in patients with cancer. Semin Oncol Nurs 29(4):288–299. https://doi.org/10.1016/j.soncn.2013.08.009
doi: 10.1016/j.soncn.2013.08.009
Green HJ, Mihuta ME, Ownsworth T, Dhillon HM, Tefay M, Sanmugarajah J, Tuffaha HW, Ng SK, Shum DHK (2019) Adaptations to cognitive problems reported by breast cancer survivors seeking cognitive rehabilitation: A qualitative study. Psycho-oncology 28(10):2042–2048. https://doi.org/10.1002/pon.5189
doi: 10.1002/pon.5189
pubmed: 31364225
Meneses K, Benz R, Bail JR, Vo JB, Triebel K, Fazeli P, Frank J, Vance DE (2018) Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot. Breast Cancer Res Treat 168(1):259–267. https://doi.org/10.1007/s10549-017-4564-2
doi: 10.1007/s10549-017-4564-2
pubmed: 29128897
Damholdt MF, Mehlsen M, O'Toole MS, Andreasen RK, Pedersen AD, Zachariae R (2016) Web-based cognitive training for breast cancer survivors with cognitive complaints-a randomized controlled trial. Psycho-oncology 25(11):1293–1300. https://doi.org/10.1002/pon.4058
doi: 10.1002/pon.4058
pubmed: 26763774
pmcid: 5111748
Kesler S, Hadi Hosseini SM, Heckler C, Janelsins M, Palesh O, Mustian K, Morrow G (2013) Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clinical breast cancer 13(4):299–306. https://doi.org/10.1016/j.clbc.2013.02.004
doi: 10.1016/j.clbc.2013.02.004
pubmed: 23647804
pmcid: 3726272
Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, Boyle F, Price MA, Vardy JL (2016) Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol 35(2):217–225. https://doi.org/10.1200/JCO.2016.67.8201
doi: 10.1200/JCO.2016.67.8201
pubmed: 28056205
Von Ah D, Carpenter JS, Saykin A, Monahan P, Wu J, Yu M, Rebok G, Ball K, Schneider B, Weaver M, Tallman E, Unverzagt F (2012) Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 135(3):799–809. https://doi.org/10.1007/s10549-012-2210-6
doi: 10.1007/s10549-012-2210-6
Wu LM, Amidi A, Tanenbaum ML, Winkel G, Gordon WA, Hall SJ, Bovbjerg K, Diefenbach MA (2018) Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer 26(6):1917–1926. https://doi.org/10.1007/s00520-017-4026-8
doi: 10.1007/s00520-017-4026-8
pubmed: 29282534
Cherrier MM, Anderson K, David D, Higano CS, Gray H, Church A, Willis SL (2013) A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci 93(17):617–622. https://doi.org/10.1016/j.lfs.2013.08.011
doi: 10.1016/j.lfs.2013.08.011
Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA (2015) Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psycho-oncology 24(11):1360–1367. https://doi.org/10.1002/pon.3769
doi: 10.1002/pon.3769
pubmed: 25759235
King S, Green HJ (2015) Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial. Front Oncol 5:72. https://doi.org/10.3389/fonc.2015.00072
doi: 10.3389/fonc.2015.00072
pubmed: 25859431
pmcid: 4373254
Green HJ, Tefay M, Mihuta ME (2018) Feasibility of small group cognitive rehabilitation in a clinical cancer setting. Psycho-oncology 27(4):1341–1343. https://doi.org/10.1002/pon.4600
doi: 10.1002/pon.4600
pubmed: 29216417
Mihuta ME, Green HJ, Shum DHK (2018) Efficacy of a web-based cognitive rehabilitation intervention for adult cancer survivors: a pilot study. Eur J Cancer Care 27(2):e12805. https://doi.org/10.1111/ecc.12805
doi: 10.1111/ecc.12805
Schuurs A, Green HJ (2013) A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psychooncology 22(5):1043–1049. https://doi.org/10.1002/pon.3102
doi: 10.1002/pon.3102
Von Ah D, Crouch A (2020) Cognitive rehabilitation for cognitive dysfunction after cancer and cancer treatment: implications for nursing practice. Semin Oncol Nurs 36(1):150977. https://doi.org/10.1016/j.soncn.2019.150977
doi: 10.1016/j.soncn.2019.150977
Fernandes HA, Richard NM, Edelstein K (2019) Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review. Support Care Cancer 27(9):3253–3279. https://doi.org/10.1007/s00520-019-04866-2
doi: 10.1007/s00520-019-04866-2
pubmed: 31147780
Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, Elter T, Galvao DA, Bloch W, Hubner ST, Wolf F (2016) Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. Biomed Res Int 2016:1820954. https://doi.org/10.1155/2016/1820954
doi: 10.1155/2016/1820954
pubmed: 27144158
pmcid: 4842032
Campbell KL, Zadravec K, Bland KA, Chesley E, Wolf F, Janelsins MC (2020) The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys Ther. https://doi.org/10.1093/ptj/pzz090
Freeman LW, White R, Ratcliff CG, Sutton S, Stewart M, Palmer JL, Link J, Cohen L (2015) A randomized trial comparing live and telemedicine deliveries of an imagery-based behavioral intervention for breast cancer survivors: reducing symptoms and barriers to care. Psychooncology 24(8):910–918. https://doi.org/10.1002/pon.3656
doi: 10.1002/pon.3656
pubmed: 25146413
Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers CA, Arun B, Palmer JL, Taylor J, Cohen L (2013) Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology 22(10):2354–2363. https://doi.org/10.1002/pon.3296
doi: 10.1002/pon.3296
pubmed: 23657969
pmcid: 6083855
Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington JE, Thomas PW (2012) Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 30(12):1335–1342. https://doi.org/10.1200/jco.2010.34.0331
doi: 10.1200/jco.2010.34.0331
pubmed: 22430268
Johns SA, Brown LF, Beck-Coon K, Talib TL, Monahan PO, Giesler RB, Tong Y, Wilhelm L, Carpenter JS, Von Ah D, Wagner CD, de Groot M, Schmidt K, Monceski D, Danh M, Alyea JM, Miller KD, Kroenke K (2016) Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors. Support Care Cancer 24(10):4085–4096. https://doi.org/10.1007/s00520-016-3220-4
doi: 10.1007/s00520-016-3220-4
pubmed: 27189614
pmcid: 5221754
Alvarez J, Meyer FL, Granoff DL, Lundy A (2013) The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther 12(6):475–487. https://doi.org/10.1177/1534735413477192
doi: 10.1177/1534735413477192
pubmed: 23584550
Johnston MF, Hays RD, Subramanian SK, Elashoff RM, Axe EK, Li J-J, Kim I, Vargas RB, Lee J, Yang L (2011) Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study. BMC Complement Altern Med 11(1):49
doi: 10.1186/1472-6882-11-49
Cimprich B (1993) Development of an intervention to restore attention in cancer patients. Cancer Nurs 16(2):83–92
doi: 10.1097/00002820-199304000-00001
Cimprich B, Ronis DL (2003) An environmental intervention to restore attention in women with newly diagnosed breast cancer. Cancer Nurs 26(4):284–292
doi: 10.1097/00002820-200308000-00005
Karschnia P, Parsons MW, Dietrich J (2019) Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol 20(2):e92–e102. https://doi.org/10.1016/S1470-2045(18)30938-0
doi: 10.1016/S1470-2045(18)30938-0
pubmed: 30723041
Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, Roscoe JA, Morrow GR (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12):2605–2616. https://doi.org/10.1002/cncr.24287
doi: 10.1002/cncr.24287
pubmed: 19309747
pmcid: 2796482
Lawrence J, Griffin L, Balcueva E, Groteluschen D, Samuel T, Lesser G, Naughton M, Case L, Shaw E, Rapp S (2016) A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv 10(1):176–184
doi: 10.1007/s11764-015-0463-x
Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429–1437
doi: 10.1093/neuonc/not114
Chan AS, Cheung M-C, Law SC, Chan JH (2004) Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 100(2):398–404. https://doi.org/10.1002/cncr.11885
doi: 10.1002/cncr.11885
pubmed: 14716777
Li X-J, Dai Z-Y, Zhu B-Y, Zhen J-P, Yang W-F, Li D-Q (2014) Effects of sertraline on executive function and quality of life in patients with advanced cancer. Med Sci Monit 20:1267–1273. https://doi.org/10.12659/MSM.890575
doi: 10.12659/MSM.890575
pubmed: 25047152
pmcid: 4114699
Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, Garrett AM (2016) A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 122(11):1782–1791. https://doi.org/10.1002/cncr.29891
doi: 10.1002/cncr.29891
pubmed: 27135464
Park JH, Jung YS, Kim KS, Bae SH (2017) Effects of compensatory cognitive training intervention for breast cancer patients undergoing chemotherapy: a pilot study. Support Care Cancer 25(6):1887–1896. https://doi.org/10.1007/s00520-017-3589-8
doi: 10.1007/s00520-017-3589-8
pubmed: 28132089
Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF (2008) A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6):577–583. https://doi.org/10.1007/s00520-007-0341-9
doi: 10.1007/s00520-007-0341-9
pubmed: 17972110
Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manag 38(5):650–662. https://doi.org/10.1016/j.jpainsymman.2009.03.011
doi: 10.1016/j.jpainsymman.2009.03.011
Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C (2014) A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J (Sudbury, Mass) 20(1):8–14. https://doi.org/10.1097/PPO.0000000000000018
doi: 10.1097/PPO.0000000000000018
Lundorff L, Jønsson B, Sjøgren P (2009) Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23(8):731–738. https://doi.org/10.1177/0269216309106872
doi: 10.1177/0269216309106872
pubmed: 19648224
Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, Wilwerding MB, Sloan JA, Kottschade LA, Rowland KM Jr, Dakhil SR, Nikcevich DA, Loprinzi CL (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21(4):1185–1192. https://doi.org/10.1007/s00520-012-1647-9
doi: 10.1007/s00520-012-1647-9
pubmed: 23150188
Chang J, Couture FA, Young SD, Lau CY, Lee McWatters K (2004) Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Cancer Ther 2(1):52–58. https://doi.org/10.3816/SCT.2004.n.023
doi: 10.3816/SCT.2004.n.023
pubmed: 18628159